tetano
Editor, Senior Moderator
Infection
. 2022 Sep 22.
doi: 10.1007/s15010-022-01917-5. Online ahead of print.
Assessment of COVID -19 associated coagulopathy and multiple hemostatic markers: a single center study in Egypt
Azza Abdelaal[SUP] 1 [/SUP], Ahmed Abu-Elfatth[SUP] 2 [/SUP], Lamees M Bakkar[SUP] 3 [/SUP], Hanan G Abd El-Azeem[SUP] 1 [/SUP], Helal F Hetta[SUP] 4 [/SUP], Eman R Badawy[SUP] 1 [/SUP]
Affiliations
Abstract
Background: Coagulopathy is still a serious pattern of coronavirus-19 disease. We aimed to evaluate COVID-19-associated coagulopathy and multiple hemostatic markers in Egyptian patients. In addition, to assess coagulation acute phase reactants and its effect on the outcome.
Methods: The study included 106 COVID-19 patients, and 51 controls. All patients were positive for COVID-19 infection by nasopharyngeal swab for detection of viral RNA by real-time PCR. In addition to baseline data and radiological findings, the coagulation profile was done with special attention to Fibrinogen, D-dimer, Factor VIII, von Willebrand factor (VWF), Protein C, Protein S, Antithrombin III (ATIII) and Lupus anticoagulant (LA)-1 and 2.
Results: The results showed significantly higher VWF, D-dimer, and LA1 (screening) and LA2 (confirmation) in patients than a control group. Significantly higher D-dimer FVIII, VWF and LA1-2 were detected in the severe group. ATIII had high diagnostic accuracy in severity prediction. We found a significantly higher international randomized ratio (INR) and VWF among patients with thrombotic events. For prediction of thrombosis; VWF at cutoff > 257.7 has 83.3% sensitivity and 83.3% specificity.
Conclusion: Patients with COVID-19 infection are vulnerable to different forms of coagulopathy. This could be associated with poor outcomes. D-Dimer is a chief tool in diagnosis, severity evaluation but not thrombosis prediction. Early screening for this complication and its proper management would improve the outcome.
Keywords: COVID-19; Coagulopathy; Egypt; Thrombosis.
. 2022 Sep 22.
doi: 10.1007/s15010-022-01917-5. Online ahead of print.
Assessment of COVID -19 associated coagulopathy and multiple hemostatic markers: a single center study in Egypt
Azza Abdelaal[SUP] 1 [/SUP], Ahmed Abu-Elfatth[SUP] 2 [/SUP], Lamees M Bakkar[SUP] 3 [/SUP], Hanan G Abd El-Azeem[SUP] 1 [/SUP], Helal F Hetta[SUP] 4 [/SUP], Eman R Badawy[SUP] 1 [/SUP]
Affiliations
- PMID: 36138306
- DOI: 10.1007/s15010-022-01917-5
Abstract
Background: Coagulopathy is still a serious pattern of coronavirus-19 disease. We aimed to evaluate COVID-19-associated coagulopathy and multiple hemostatic markers in Egyptian patients. In addition, to assess coagulation acute phase reactants and its effect on the outcome.
Methods: The study included 106 COVID-19 patients, and 51 controls. All patients were positive for COVID-19 infection by nasopharyngeal swab for detection of viral RNA by real-time PCR. In addition to baseline data and radiological findings, the coagulation profile was done with special attention to Fibrinogen, D-dimer, Factor VIII, von Willebrand factor (VWF), Protein C, Protein S, Antithrombin III (ATIII) and Lupus anticoagulant (LA)-1 and 2.
Results: The results showed significantly higher VWF, D-dimer, and LA1 (screening) and LA2 (confirmation) in patients than a control group. Significantly higher D-dimer FVIII, VWF and LA1-2 were detected in the severe group. ATIII had high diagnostic accuracy in severity prediction. We found a significantly higher international randomized ratio (INR) and VWF among patients with thrombotic events. For prediction of thrombosis; VWF at cutoff > 257.7 has 83.3% sensitivity and 83.3% specificity.
Conclusion: Patients with COVID-19 infection are vulnerable to different forms of coagulopathy. This could be associated with poor outcomes. D-Dimer is a chief tool in diagnosis, severity evaluation but not thrombosis prediction. Early screening for this complication and its proper management would improve the outcome.
Keywords: COVID-19; Coagulopathy; Egypt; Thrombosis.